Dysregulation of the RAS-MAPK signaling pathway has recently been recognized as the molecular cause underlying a group of clinically related developmental disorders with features including reduced growth, facial dysmorphism, cardiac defects, ectodermal anomalies, variable cognitive deficits and susceptibility to certain malignancies[@R8],[@R9]. These Mendelian traits are caused by mutations in genes encoding RAS proteins (*KRAS* and *HRAS*), downstream transducers (*RAF1*, *BRAF*, *MEK1* and *MEK2*), or pathway regulators (*PTPN11*, *SOS1*, *NF1* and *SPRED1*). For NS (NS), the commonest of these disorders, mutations are observed in several of these, constituting approximately 70% of cases.

To rationalize further candidate gene approaches to NS gene discovery, we used a systems biology approach based on *in silico* protein network analysis. By applying a graph theory algorithm on a filtered consolidated human interactome, we derived a subnetwork of proteins generated from an integrated network of mammalian protein interaction databases and cell-signaling network datasets by seeding with the known RAS/MAPK mutant proteins ([Supplementary Fig. 1a](#SD1){ref-type="supplementary-material"} online). To identify potential NS disease genes, Z scores were computed using a binomial proportions test, ranking the significance of the intermediate nodes within the subnetwork based on their connections to the seed proteins[@R10] ([Supplementary Table 1](#SD1){ref-type="supplementary-material"} online). Resequencing of coding exons for the best candidate, *SHOC2*, in a NS cohort including 96 individuals who were negative for mutations in known disease genes and opportunely selected to represent the wide phenotypic spectrum characterizing this disorder revealed an A-to-G transition at position 4 of the gene, predicting the Ser2Gly amino acid substitution (S2G), in four unrelated individuals ([Supplementary Fig. 1b](#SD1){ref-type="supplementary-material"} online). All cases were sporadic, and genotyping of parental DNAs available for three of the four subjects documented the absence of the sequence variant in the parents and confirmed paternity in each family, providing evidence that the change was a *de novo* mutation associated with the disease. For these subjects, DNAs from several tissues were available and all harboured the S2G mutation, providing evidence that the defect was inherited through the germline. We then analyzed *SHOC2* in a cohort of 410 mutation-negative subjects with NS or a related phenotype. We observed 21 with the 4A\>G missense change and proved that mutations were *de novo* in twelve families from which parental DNAs were available. No additional disease-associated *SHOC2* sequence variant was identified in the analyzed cohort, strongly suggesting a specific pathogenetic role for the S2G amino acid substitution.

Review of the clinical features of the *SHOC2* mutation-positive individuals revealed a consistent phenotype, previously termed Noonan-like syndrome with loose anagen hair [@R7]. While their facial features seemed typical for NS ([Fig. 1a](#F1){ref-type="fig"}), phenotype analysis of these subjects was notable for the observation that they exhibited reduced growth, which was frequently associated with proven GH deficiency, cognitive deficits, distinctive hyperactive behaviour that improved with age in most subjects, and hair anomalies including easily pluckable, sparse, thin, slow growing hair. In twelve subjects, a diagnosis of loose anagen hair was confirmed by microscopic examination of pulled hairs. Most of them also exhibited darkly pigmented skin with eczema or ichthyosis. Cardiac anomalies were observed in the majority of the cases, with dysplasia of the mitral valve and septal defects significantly overrepresented compared with the general NS population. The voice was characteristically hypernasal. Of note, the referring pediatricians felt that several of these subjects had features suggestive of Costello syndrome or cardiofaciocutaneous syndrome, as newborns or young infants. Overall, these subjects appeared to share a phenotype that was characterized by an unusual combination of features observed in disorders of the neuro-cardio-facial-cutaneous disorders family ([Supplementary Table 2](#SD1){ref-type="supplementary-material"} online).

SHOC2 is a widely expressed protein composed almost entirely by leucine-rich repeats (LRR) with a lysine-rich sequence at the *N*-terminus ([Fig. 1b](#F1){ref-type="fig"}). In *C. elegans*, where SHOC2/SUR-8/SOC-2 was discovered, the protein acts as a positive modulator of the signal transduction elicited by EGL-15 and LET-23, and mediated by LET-60, homologues of vertebrate FGFR, EGFR and RAS family members, respectively[@R3],[@R4]. Since LRRs can provide a structural framework for protein-protein interactions, SHOC2 is believed to function as a scaffold linking RAS to downstream signal transducers[@R4]--[@R6]. Based on the *N*-terminal position of the S2G substitution, we hypothesized that co-translational processing might be perturbed in the mutant protein, making it a substrate for the *N*-myristoyltransferase (NMT). *N*-terminal myristoylation is an irreversible modification generally occurring during protein synthesis, in which myristate, a 14-carbon saturated fatty acid, is covalently added to an *N*-terminal glycine residues after excision of the initiator methionine residue by methionylaminopeptidase[@R1],[@R2]. Glycine at codon 2 is absolutely required, small uncharged residues at positions 3 and 6 are generally needed, and basic residues at positions 7--9 are preferred[@R11]. Save the presence of Ser at position 2, the *N*-terminal sequence of the SHOC2 satisfied those consensus rules, and *in silico* analysis predicted myristoylation of the SHOC2^S2G^ mutant with high confidence. To verify this, the myristoylation status of wild type and mutant SHOC2 proteins transiently expressed in Cos-1 cells was evaluated ([Fig. 2a](#F2){ref-type="fig"}). SHOC2^S2G^ incorporated \[^3^H\]-myristic acid, while the wild type protein and the disease-unrelated SHOC2^S2A^ did not.

*N*-myristoylation facilitates anchoring of proteins to intracellular membranes. To explore whether it conferred membrane targeting to mutant SHOC2, the subcellular localization of V5-tagged SHOC2 proteins was analyzed in Cos-1 cells ([Fig. 2b,d](#F2){ref-type="fig"}). Confocal laser scanning microscopy analysis documented that SHOC2^wt^ was uniformly distributed in the cytoplasm and nucleus in starved cells but was restricted to the nucleus following EGF stimulation, implying an unexpected role for this protein in signal transduction. In contrast, SHOC2^S2G^ was specifically targeted to the cell membrane in both states. This aberrant localization of SHOC2^S2G^ was confirmed in 293T and Neuro2A cell lines and using a Myc-tagged protein (data not shown), as well as by cell fractionation ([Fig. 2c](#F2){ref-type="fig"}). Growth factor-stimulated nuclear translocation of the endogenous SHOC2 protein was confirmed in primary skin fibroblasts ([Fig. 2e](#F2){ref-type="fig"}). Treatment with 2-hydroxymyristic acid, an NMT inhibitor, at varying doses reduced or abolished SHOC2^S2G^'s membrane localization ([Supplementary Fig. 2](#SD1){ref-type="supplementary-material"} online), confirming a dependency upon myristoylation. In addition, even in the absence of efficient myristoylation, the mutant did not translocate to the nucleus upon stimulation, indicating possible loss of function. Efficient nuclear translocation was observed for the disease-unrelated SHOC2^S2A^ mutant following EGF stimulation ([Supplementary Fig. 3](#SD1){ref-type="supplementary-material"} online), suggesting a specific effect of the disease-causing mutation. To exclude the possibility that SHOC2^S2G^ might play a dominant negative effect by sequestering the wild-type protein to the cell membrane, impairing its EGF-dependent translocation to the nucleus, SHOC2^wt^ and SHOC2^S2G^ heterodimerization was assayed by confocal microscopy and co-immunoprecipitation assays in Cos-1 cells transiently co-transfected with V5- and Myc-tagged proteins ([Fig. 3a,b](#F3){ref-type="fig"}). The experiments demonstrated that these proteins do not heterodimerize, ruling out that possibility. Next, we explored whether SHOC2^S2G^ altered signaling through MAPK. We expressed SHOC2^wt^ or SHOC2^S2G^ in Cos-1, 293T, and Neuro2A cells. While we did not observe significant change in ERK activation in Cos-1 and 293T cells (data not shown), SHOC2^S2G^ expression promoted enhanced EGF-dependent ERK phosphorylation compared to wild type SHOC2, in neuroblastoma Neuro2A cells ([Fig. 3c](#F3){ref-type="fig"}).

To explore further the functional effects of the SHOC2^S2G^ mutant, we used *C. elegans* as an experimental model. In *C. elegans*, reduced SUR-8 function (*Sur8^rf^*) causes no phenotype but can suppress the gain-of-function LET-60 (*let-60^gof^*)-induced multivulva phenotype (Muv)[@R4]. We tested whether expression of SHOC2 proteins could rescue the suppressed Muv phenotype in the *sur-8^rf^*;*let-60^gof^* genetic background ([Supplementary Table 3](#SD1){ref-type="supplementary-material"} online). While SHOC2^wt^ was able to replace SUR-8 functionally, SHOC2^S2G^ failed to do so. Expression of the mutant in *let-60^gof^* worms did not suppress the Muv phenotype ([Supplementary Table 3](#SD1){ref-type="supplementary-material"} online), excluding dominant negative effects for SHOC2^S2G^. In a wild-type genetic background, SHOC2^S2G^ expression at embryonic and early larval stages of development caused no visible phenotype. In contrast, at early L3 stage, it caused abnormal vulval development, resulting in protruding vulva (Pvl), decreased egg laying efficiency (Egl) and accumulation of larvae inside the mother with the formation of bag-of-worms adults (Bag phenotype) ([Supplementary Table 4](#SD1){ref-type="supplementary-material"} online and [Fig. 4b,c](#F4){ref-type="fig"}). These neomorphic phenotypes were absent in animals expressing SHOC2^wt^ but were also observed when SHOC2^wt^ tagged with an *N*-myristoylation sequence (myr::SHOC2^wt^) was expressed ([Supplementary Table 4](#SD1){ref-type="supplementary-material"} online and [Fig. 4a,d](#F4){ref-type="fig"}). The SHOC2^S2G^ and myr::SHOC2^wt^ proteins were targeted to the cell membrane in various *C. elegans* cell types, while SHOC2^wt^ was observed diffusely throughout the cytoplasm and nucleus ([Fig. 4e--j](#F4){ref-type="fig"}). The defects in vulva formation were not due to increased induction of the vulva cell fate in vulval precursor cells (VPC) as expression of SHOC2^S2G^ did not reduce the penetrance of the vulvaless phenotype of a *let-23^rf^* hypomorph mutant ([Supplementary Table 5](#SD1){ref-type="supplementary-material"} online), nor increase that of the Muv phenotype of *let-60^gf^* animals ([Supplementary Table 3](#SD1){ref-type="supplementary-material"} online). At the late L3/early L4 stage, vulva morphogenesis normally begins with the descendants of VPC P6.p detaching from the cuticle and forming a symmetric invagination. Animals in which the expression of SHOC2^wt^ had been induced at early L3 maintained this pattern. In contrast, in larvae expressing SHOC2^S2G^ (17/48) or myr::SHOC2^wt^ (10/22), descendants of VPCs P5.p and/or P7.p also detached from the cuticle, resulting in larger and asymmetric invaginations ([Fig. 4k--n](#F4){ref-type="fig"}). This morphogenesis defect was the earliest detectable neomorphic effect of the SHOC2^S2G^ mutation on vulval development.

We discovered that a *SHOC2* mutation promoting *N*-myristoylation of its protein product causes Noonan-like syndrome with loose anagen hair. This acquired fatty acid modification, a unique finding for inherited human disease, results in constitutive membrane targeting, leading to increased MAPK activation in a cell context-specific manner. Cell-specific RAS pathway activation has also been observed with NS-associated SHP-2 mutants.[@R12]--[@R14] While not well understood, this phenomenon explains why, despite the ubiquitousness of RAS signaling, development is perturbed in certain tissues in these disorders. It has recent been reported that SHOC2 functions as a regulatory subunit of the catalytic subunit of protein phosphatase 1 (PP1C)[@R6]. By binding GTP-MRAS, SHOC2 promotes PP1C translocation to the membrane, allowing PP1C-mediated RAF1 dephosphorylation at residue Ser259, which is required for stable RAF1 translocation to the plasma membrane and catalytic activation. Of note, Ser259 and adjacent residues, which represent a 14-3-3 protein binding site with inhibitory function, are a major hot spot for NS-causing mutations in RAF1 (Ref. [@R9]). According to this model, constitutive membrane translocation of the disease-causing SHOC2^S2G^ is expected to promote prolonged PP1C-mediated RAF1 dephosphorylation at Ser259 and, consequently, sustained RAF1-stimulated MAPK activation, which is consistent with our findings.

In *C. elegans*, *N*-myristoylated SHOC2 expression altered morphogenesis during vulval development, a process for which the involvement of Ras signaling is well established. Specification of VPCs, however, was not altered. Rather, perturbation of the morphogenetic movements of the VPC descendant cells was observed. While numerous mutants altering vulval specification and morphogenesis have been identified, far less is known about processes affecting only morphogenesis[@R15],[@R16]. It is possible that SHOC2^S2G^ alters Ras signaling in steps downstream of the induction of the vulval fate. Alternatively, SHOC2^S2G^-induced vulva defects might arise through perturbation of signaling pathways other than Ras-MAPK, such as signaling mediated by the Rho GTPase, Rac, which are critical for vulval morphogenesis[@R17].

A unique feature of the *SHOC2* mutation is its association with loose anagen hair. This phenotype occurs in isolation or with NS and has been without molecular cause. Hair shafts from affected individuals show features of the anagen stage of hair follicle development, during which epithelial stem cells proliferate in the hair bulb[@R18]. In this condition, however, hair bulbs lack internal and external root sheaths. Our findings suggest perturbation in the proliferation, survival or differentiation of epithelial stem cell-derived cells residing in hair follicles, and implicate SHOC2-mediated signal transduction in this aspect of stem cell biology.

Lastly, we successfully used the human interactome and a network-based statistical method to predict a novel gene for human disease. Our leading candidate, *SHOC2*, was a relatively obscure gene that caused no phenotype when mutated in worms, evidence of the strength of this approach. For other projects, one can anticipate that successful candidates will not be deemed this favourable, necessitating resequencing of many low-probability candidate genes. Emerging interactome datasets and improved analytic methods are likely to enhance the predictive power of systems biology.
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![The germline 4A\>G mutation in the *SHOC2* gene underlies a distinctive phenotype of the neuro-cardio-facial-cutaneous syndrome family\
(a) Representative phenotypic features of affected subjects carrying the *SHOC2* mutation. Common features include macrocephaly, high forehead, hypertelorism, palpebral ptosis, low-set/posteriorly rotated ears, short and webbed neck, and pectus anomalies. Affected subjects also exhibited easily pluckable, sparse, thin, slow-growing hair. (b) *SHOC2* genomic organization and protein structure. The coding exons are shown at the top as numbered filled boxes. Intronic regions are represented by dotted lines. SHOC2's motifs comprise an *N*-terminal lysine-rich region (grey coloured; Prosite motif score = 8.8) followed by 19 leucine-rich repeats (Pfam hits with an E-value \<0.5 are black coloured, while those with an E-value \>1 are represented in white). Numbers above the domain structure indicate the amino acid boundaries of those domains.](nihms131154f1){#F1}

![The disease-causing 4A\>G change in *SHOC2* promotes protein myristoylation and cell membrane targeting\
(a) \[^3^H\]myristic acid incorporation (middle) occurs in SHOC2^S2G^ but not in SHOC2^wt^ or SHOC2^S2A^. Equivalent levels of SHOC2 proteins in immunoprecipitates (left) and \[^3^H\]myristic acid incorporation in cells (right) are shown. (b) SHOC2^wt^ is uniformly present in the cytoplasm and nucleus in starved Cos-1 cells (upper left) and is restricted to the nucleus following EGF stimulation (upper right), while SHOC2^S2G^ is targeted to the cell membrane basally (lower left) and after stimulation (lower right). Confocal microscopy visualized SHOC2 (anti-V5 monoclonal antibody, then Alexa Fluor-594 goat anti-mouse antibody; red), actin cytoskeleton (Alexa Fluor 488-phalloidin; green) and nuclei (DAPI; blue). (c) Cell fractioning assay documenting preferential membrane targeting of SHOC2^S2G^. Transiently transfected cells were serum-starved or stimulated with EGF, and lysates were fractionated to separate membrane-associated proteins. ERBB2 is shown to demonstrate equivalent fractionation efficiency, while anti-V5 blot from cell lysates show equivalent transfection efficiency. (d) Co-localization of V5-tagged SHOC2^S2G^ and ganglioside M1 to the plasma membrane in Cos-1 cells. Subcellular localization of V5-tagged wild type SHOC2 (left) and V5-tagged SHOC2^S2G^ (right) is shown. Ganglioside M1 was detected by using the Vybrant Lipid Raft Labeling kit (green). SHOC2 proteins and nuclei are visualized as reported above. Cells were cultured in DMEM supplemented with 10% heat-inactivated FBS. (e) Subcellular localization of the endogenous SHOC2^wt^ protein in primary skin fibroblasts, basally (left) and following stimulation (right). Confocal microscopy was performed using an anti-SHOC2 polyclonal antibody, followed by Alexa Fluor 594 goat anti-rabbit antibody (red), while actin cytoskeleton was detected by Alexa Fluor 488-phalloidin (green). All images represent single optical sections representative of \> 50 transfected cells observed in each experiment. Bars indicate 20 µm (b and d) or 40 µm (e).](nihms131154f2){#F2}

![Functional characterization of the disease-causing 4A\>G change in *SHOC2*\
(a) Subcellular localization of co-expressed SHOC2^wt^ (green) and SHOC2^S2G^ (red) documenting that SHOC2^S2G^ does not impair EGF-stimulated SHOC2^wt^ translocation to the nucleus. Imaging of V5-tagged (anti-V5 monoclonal antibody, then Alexa Fluor-594 goat anti-mouse antibody) and Myc-tagged (anti-Myc antibody, then Alex Fluor 488 goat anti-rabbit antibody) SHOC2 proteins and nuclei (DAPI, blue). Panels above show Myc-tagged SHOC2^wt^ and V5-tagged SHOC2^S2G^ and below show V5-tagged SHOC2^wt^ and Myc-tagged SHOC2^S2G^. Cells were imaged basally (left) and following EGF stimulation (right). Bars indicate 20 µm. (b) Lysates of Cos-1 cells co-expressing Myc-tagged SHOC2^wt^ and V5-tagged SHOC2^S2G^ were immunoprecipitated using anti-Myc (above panel) or anti-V5 (below panel) antibody, and immunoprecipitated proteins were visualized by western blotting. These results indicate that SHOC2 proteins do not form heterodimers. (c, d) ERK phosphorylation in V5-tagged SHOC2^wt^ or SHOC2^S2G^ transiently expressed Neuro2A cells basally or following EGF stimulation. Phosphorylation levels are reported as a multiple of basal ERK phosphorylation in cells not transfected with a SHOC2 construct, averaged from four replicates ± s.d. (c). Results for cells expressing the S2G mutant were compared with those overexpressing the wild type protein (below) or untransfected cells (above) at the same time points using two-tailed *t*-test. \* indicates *P* \< 0.05, \*\* indicates *P* \< 0.01, \*\*\* indicates *P* \< 0.001. Representative blots are also shown (d).](nihms131154f3){#F3}

![Consequences of SHOC2^S2G^ expression in *C. elegans* vulva development\
(a--d) Nomarski images of vulvas of adult animals. A normal vulva is observed in animals expressing SHOC2^wt^ (a), while in worms expressing SHOC2^S2G^ (b and c) or myr::SHOC2^wt^ (d) a protrusion of the vulva is visible. (e--j) Subcellular localization of V5-tagged SHOC2 proteins in *C. elegans* cells. In excretory canal cells (e--g) and intestinal cells (h--j), SHOC2^wt^ protein is present throughout the cytoplasm (e and h), while both SHOC2^S2G^ (f and i) and myr::SHOC2^wt^ (g and j) are enriched in or restricted to the plasma membrane. Anti-V5 antibody (red) was used to visualize SHOC2 proteins. In intestinal cells, nuclei express GFP due to pelt-2::GFP plasmid used as a marker for transformation. (k--n) Nomarski images of vulval precursor cells at L3 stage. In animals expressing SHOC2^wt^ only P6.p descendant invaginate (k), while in SHOC2^S2G^ (l and m) and myr::SHOC2^wt^ (n) expressing animals also P5.p (l to n) and P7.p descendants (m and n) detach from the cuticle. Black arrowheads point to P6.p descendant invagination, while white arrowheads point to P5.p and P7.p descendant invagination. Anterior is to the left and dorsal is up in all images.](nihms131154f4){#F4}
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